Literature DB >> 29439954

Fine-tuning of FOXO3A in cHL as a survival mechanism and a hallmark of abortive plasma cell differentiation.

Clarissa D Osswald1, Linka Xie2, Hanfeng Guan3, Franziska Herrmann1, Sarah M Pick1, Marion J Vogel1, Franziska Gehringer1, Fong Chun Chan4, Christian Steidl4, Thomas Wirth1, Alexey Ushmorov1.   

Abstract

We recently found that FOXO1 repression contributes to the oncogenic program of classical Hodgkin lymphoma (cHL). Interestingly, FOXO3A, another member of the FOXO family, was reported to be expressed in the malignant Hodgkin and Reed-Sternberg cells of cHL at higher levels than in non-Hodgkin lymphoma subtypes. We thus aimed to investigate mechanisms responsible for the maintenance of FOXO3A as well as the potential role of FOXO3A in cHL. Here, we show that high FOXO3A levels in cHL reflect a B-cell-differentiation-specific pattern. In B cells, FOXO3A expression increases during the process of centroblast to plasma cell (PC) differentiation. FOXO3A levels in cHL were found higher than in germinal center B cells, but lower than in terminally differentiated PCs. This intermediate FOXO3A expression in cHL might manifest the "abortive PC differentiation" phenotype. This assumption was further corroborated by the finding that overexpression of FOXO3A in cHL cell lines induced activation of the master PC transcription factor PRDM1α. As factors attenuating FOXO3A expression in cHL, we identified MIR155 and constitutive activation of extracellular signal-regulated kinase. Finally, we demonstrate the importance of FOXO3A expression in cHL using an RNA interference approach. We conclude that tightly regulated expression of FOXO3A contributes to the oncogenic program and to the specific phenotype of cHL.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29439954      PMCID: PMC5887767          DOI: 10.1182/blood-2017-07-795278

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  73 in total

1.  β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer.

Authors:  Stephan P Tenbaum; Paloma Ordóñez-Morán; Isabel Puig; Irene Chicote; Oriol Arqués; Stefania Landolfi; Yolanda Fernández; José Raúl Herance; Juan D Gispert; Leire Mendizabal; Susana Aguilar; Santiago Ramón y Cajal; Simó Schwartz; Ana Vivancos; Eloy Espín; Santiago Rojas; José Baselga; Josep Tabernero; Alberto Muñoz; Héctor G Palmer
Journal:  Nat Med       Date:  2012-06       Impact factor: 53.440

2.  FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis.

Authors:  R van Boxtel; C Gomez-Puerto; M Mokry; A Eijkelenboom; K E van der Vos; E E S Nieuwenhuis; B M T Burgering; E W-F Lam; P J Coffer
Journal:  Cell Death Differ       Date:  2013-07-05       Impact factor: 15.828

3.  Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma.

Authors:  Franziska Jundt; Ioannis Anagnostopoulos; Reinhold Förster; Stephan Mathas; Harald Stein; Bernd Dörken
Journal:  Blood       Date:  2002-05-01       Impact factor: 22.113

4.  Tumorigenic potential of mononucleated small cells of Hodgkin lymphoma cell lines.

Authors:  Jun-ichiro Ikeda; Suhana Mamat; Tian Tian; Yi Wang; Nur Rahadiani; Katsuyuki Aozasa; Eiichi Morii
Journal:  Am J Pathol       Date:  2010-10-15       Impact factor: 4.307

5.  TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia.

Authors:  Kazuhito Naka; Takayuki Hoshii; Teruyuki Muraguchi; Yuko Tadokoro; Takako Ooshio; Yukio Kondo; Shinji Nakao; Noboru Motoyama; Atsushi Hirao
Journal:  Nature       Date:  2010-02-04       Impact factor: 49.962

6.  FOXO1-mediated activation of Akt plays a critical role in vascular homeostasis.

Authors:  Harita Dharaneeswaran; Md Ruhul Abid; Lei Yuan; Dylan Dupuis; David Beeler; Katherine C Spokes; Lauren Janes; Tracey Sciuto; Peter M Kang; Shou-Ching S Jaminet; Ann Dvorak; Marianne A Grant; Erzsébet Ravasz Regan; William C Aird
Journal:  Circ Res       Date:  2014-05-29       Impact factor: 17.367

7.  Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma.

Authors:  Christian Steidl; Arjan Diepstra; Tang Lee; Fong Chun Chan; Pedro Farinha; King Tan; Adele Telenius; Lorena Barclay; Sohrab P Shah; Joseph M Connors; Anke van den Berg; Randy D Gascoyne
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

8.  Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma.

Authors:  Enrico Tiacci; Claudia Döring; Verena Brune; Carel J M van Noesel; Wolfram Klapper; Gunhild Mechtersheimer; Brunangelo Falini; Ralf Küppers; Martin-Leo Hansmann
Journal:  Blood       Date:  2012-09-05       Impact factor: 22.113

9.  FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines.

Authors:  Andrew Sunters; Silvia Fernández de Mattos; Marie Stahl; Jan J Brosens; Georgia Zoumpoulidou; Catherine A Saunders; Paul J Coffer; René H Medema; R Charles Coombes; Eric W-F Lam
Journal:  J Biol Chem       Date:  2003-10-03       Impact factor: 5.157

10.  FOXO1 downregulation contributes to the oncogenic program of primary mediastinal B-cell lymphoma.

Authors:  Linka Xie; Olga Ritz; Frank Leithäuser; Hanfeng Guan; Johanna Färbinger; Clarissa D Weitzer; Franziska Gehringer; Silke Bruederlein; Karlheinz Holzmann; Marion J Vogel; Peter Möller; Thomas Wirth; Alexey Ushmorov
Journal:  Oncotarget       Date:  2014-07-30
View more
  6 in total

1.  PPP2CA Is a Novel Therapeutic Target in Neuroblastoma Cells That Can Be Activated by the SET Inhibitor OP449.

Authors:  Celimene Galiger; Meike Dahlhaus; Michael Peter Vitek; Klaus-Michael Debatin; Christian Beltinger
Journal:  Front Oncol       Date:  2022-06-22       Impact factor: 5.738

2.  Revealing the Critical Regulators of Cell Identity in the Mouse Cell Atlas.

Authors:  Shengbao Suo; Qian Zhu; Assieh Saadatpour; Lijiang Fei; Guoji Guo; Guo-Cheng Yuan
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

3.  Chlorzoxazone, a small molecule drug, augments immunosuppressive capacity of mesenchymal stem cells via modulation of FOXO3 phosphorylation.

Authors:  Luchan Deng; Hongling Li; Xiaodong Su; Yingjie Zhang; Haoying Xu; Linyuan Fan; Junfen Fan; Qin Han; Xueyuan Bai; Robert Chunhua Zhao
Journal:  Cell Death Dis       Date:  2020-03-02       Impact factor: 8.469

4.  FOXO1 Confers Maintenance of the Dark Zone Proliferation and Survival Program and Can Be Pharmacologically Targeted in Burkitt Lymphoma.

Authors:  Franziska Gehringer; Stephanie E Weissinger; Lotteke Jym Swier; Peter Möller; Thomas Wirth; Alexey Ushmorov
Journal:  Cancers (Basel)       Date:  2019-09-25       Impact factor: 6.639

5.  Transcriptional circuitry atlas of genetic diverse unstimulated murine and human macrophages define disparity in population-wide innate immunity.

Authors:  Bharat Mishra; Mohammad Athar; M Shahid Mukhtar
Journal:  Sci Rep       Date:  2021-04-01       Impact factor: 4.379

6.  AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.

Authors:  Timon A Bloedjes; Guus de Wilde; Chiel Maas; Eric Eldering; Richard J Bende; Carel J M van Noesel; Steven T Pals; Marcel Spaargaren; Jeroen E J Guikema
Journal:  Blood Adv       Date:  2020-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.